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ABSTRACT 
The hedgehog signaling pathway plays a major role in cellular functions such as 
differentiation, proliferation and survival. Consequently due to any alterations in this pathway 
results in cellular deficiencies leading to disease conditions especially cancer. The fundamental 
abnormality resulting in the development of cancer is the continual unregulated proliferation of 
cancer cells. Rather than responding appropriately to signals that control normal cell behavior, 
cancer cell grow and divide in an uncontrolled manner, invading normal tissues and organs and 
eventually spreading throughout the body. Activation of HH pathway responsible for initiation 
and proliferation of neoplastic changes is usually a result of genetic alterations of the HH 
pathway components. The present study has been conducted to decrypt the epigenetic regulatory 
mechanisms controlling HH pathway in prostate cancer. Epigenetic modulators are involved in 
deregulation of HH pathway will provide opportunity for creating novel strategies for therapeutic 
approach for cancer treatment. 
 
Keywords: Hedgehog signaling pathway, Prostate cancer, Epigenetic  
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INTRODUCTION 
During development there are various transformation takes place, one such example is that a 
single cell is transformed to a multicellular entity, which actually happened by a well-developed 
signal transduction pathway. The signal transduction pathway mainly involves the, the HH 
signaling pathway. The HH signaling pathway is a signaling pathway that helps in transmission 
of information to embryonic cells for proper and well-development. Different concentration of 
hedgehog signaling proteins are present in different parts of the embryo. The HH signaling has a 
key role during this development. It takes part in cell proliferation, cell fate determination, 
epithelial to mesenchymal transitions and the rearrangement of cells by motility and adhesion 
changes, thus making an affect from embryonic development. This overall activity is 
significantly marking from embryogenesis. But HH pathway also important in stem cell 
maintenance, tissue repair and regeneration in adult physiology. HH signaling pathway is also 
associated with Wnt, NOTCH, RAS pathways. Thus, HH pathway has become an essential 
component of cellular differentiation activity. 
                    When there is Neoplasm occurs in the cell, it entirely changes the molecular activity 
of the cell and it is involved in tumor growth and cancer metastasis. The problem involved in 
this, is that it deregulates the cellular signaling pathways that maintains the homeostasis balance 
between cell growth and cell death as one need to maintain the homeostasis for proper 
development, especially the physiological system of higher animals. It also stimulates the 
oncogenic signaling pathways by depending on the advantageous properties of survival and 
proliferation on tumor cells. In any circumstances, when the hedgehog signaling pathway leads 
to abnormality it causes physiological disorders, which results in various cancers like- 
gastrointestinal cancer, medulloblastoma, pancreatic cancer etc. The uncontrolled activity of HH 
pathways causes deregulation of molecular and physiological activity such as cell proliferation, 
increased tumor invasiveness etc. Thus to maintain the homeostasis and to control the cell 
proliferation associated with tumor, so as to need to thwart the HH pathway, need to manipulate 
the HH signaling pathway. 
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A figure has been included here to get the basic knowledge about the presence or absence of 
ligands with HH pathway components: 
 
Figure 1: In this figure it is showed that when there is an absence of ligand Ci gets cleaved and 
transcription does not occur where as in the presence of ligand Ci does not cleaved and 
transcription occurs in the Nucleus. 
Cancer (a life threatening disease) is up-regulated by various HH ligands like SHH (Sonic 
hedgehog), IHH (Indian hedgehog) and DHH (Desert hedgehog) and pathway components are 
PTCH (Patched), SMO (Smoothened), SUFU (Suppressor of fused), GLI or by genetic and 
epigenetic modification in the pathway. Loss-of-function mutations (a mutation that results in 
reduced or abolished protein function) in PTCH and SUFU, Gain-of-function mutations (Which 
are much less common, confer an abnormal activity on a protein) in SMO and missense 
mutations in GLI1 and GLI3 has been largely involved in genetic alteration of HH signaling 
pathway. 
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                      There are various epigenetic changes occur in HH pathway which leads to aberrant 
changes. It gives an idea that both genetic and epigenetic works simultaneously to disturb the 
normal HH pathway activity and further this leads to tumorgenesis. The present study says that 
the deregulation activity of HH pathway can be controlled by some epigenetic drugs. A 
comparative analysis of the gene expression profile of the different HH pathway components 
such as SHH, PTCH, SMO and GLI1 after treatment with epigenetic drugs and modulators will 
be done. The project mainly emphasize on the effect of drug to the deregulated HH signaling 
pathway. The various epigenetic drugs will have a marking effect against the various challenging 
cancers. And these can have clinical implications and can be used as therapeutics. 
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REVIEW OF LITERATURE 
Scenario of Hedgehog Signaling pathway: 
Hedgehog (HH) was first discovered by Christiane Nusslein-Volhard and Erio Weischaus in fruit 
flies of the genus Drosophila. Hedgehog name originally derives from the short and “spiked” 
phenotype of the cuticle of the HH mutant Drosophila larvae. Including Drosophila, HH genes 
have also been found in other invertebrates like Hirudo medicinal (leech) and Diadema 
antillarum (sea urchin) (chans et al, 1994). HH signaling pathway consists of various subgroups 
like SHH (Sonic hedgehog), IHH (Indian hedgehog) and DHH (Desert hedgehog).  
1. SHH: This stands for sonic hedgehog. It is a protein that in humans is encoded by the 
SHH gene. SHH ligand of the HH signaling pathway is mostly studied. It has its own 
importance in regulating vertebrate organogenesis, such as in the growth of digits on 
limbs and organization of the brain. The term morphogen given by Lewis wolpert, which 
are signaling molecules that originate from a restricted region of a tissue and spread away 
from their source to form a concentration gradient. The best example of morphogen is 
sonic hedgehog which has been explained by Lewis wolpert’s French flag model. Cell 
division of adult stem cells is controlled by SHH and has been ramification in the 
development of some cancers. 
 
2. IHH: Indian hedgehog also called as IHH. It is a protein which in humans is encoded 
by the IHH gene. The Indian hedgehog protein is one of the three proteins in the 
mammalian hedgehog family. It participates in chondrocyte differentiation, proliferation 
and maturation especially during endochondral ossification. It regulates its effects by 
feedback control of parathyroid hormone-related peptide (PTHrP). 
 
3. DHH: Desert hedgehog protein is a protein that in humans is encoded by the DHH 
gene. It has a key role in regulating morphogenesis. This protein is made as a precursor 
that is auto catalytically cleaved; the N-terminal portion is soluble and contains the 
signaling activity while the C-terminal portion is involved in precursor processing. 
Abnormality in this protein have been associated with partial gonadal digenesis (PGD) 
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accompanied by minifascicular polyneuropathy (it is a damage or disease affecting 
peripheral nerves). 
 
Receptor complex of Hedgehog signaling pathway:  
PATCHED (PTCH): This is an essential gene in embryogenesis that is important for proper 
segmentation in the fly embryo, mutations in which may be embryonic lethal. Function of 
patched for the hedgehog protein is like receptor. The mutations in the ptch were discovered in 
the fruit fly Drosophila melanogaster by 1995 Nobel laureates Eric F. Weischaus and Christiane 
Nusslein-volhard.  
SMOOTHENED (SMO): This is a protein that in humans is encoded by the SMO gene. It is the 
molecular target of the teratogen Cyclopamine. It is a heptahelical transmembrane segment.  
GLI: The transcription factor GLI protein present in five-zinc finger including GLI1, GLI2 and 
GLI3. These are the chief downstream effector molecules of hedgehog signaling pathway. These 
three receptor complex can be act together which can be depict through the figure. The figure 
shows two cases first one is in the absence of HH ligand and the second one is the presence of 
HH ligand. For activation of these receptor complexes we need HH ligand. 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                    Figure 2: An overview of HH signaling pathway. 
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The above figure depicts that in the absence of HH ligand, SMO is blocked by PTCH, GLI 
proteins are perpetuate in the cytoplasm with other proteins such as kinesin-like COSTAL2, the 
serine-threonine kinase fused and suppressor of fused (SUFU), transcriptionally silent GLI1, 
GLI2 is phosphorylated by glycogen synthase kinase 3 (GSK3), Casein kinase1 (CK1) and 
protein kinase A (PKA) and subsequently degraded by proteolysis and GLI3 is present mostly as 
a cleaved repressor thus resulting in transcriptional silencing of HH-GLI target genes (Katoh and 
Katoh., 2008). But when the HH ligand binds to PTCH, it enables SMO translocation to the 
primary cilium and prevents the suppressive kinase action on GLI factors. As a result GLI1 is 
activated transcriptionally, GLI2 becomes an activator and GLI3 is no longer cleaved. In the 
nucleus, assembling of GLI activator results in increased expression of a number of HH target 
genes, eminent among them being PTCH, GLI, insulin-like growth factor2 (IGF2), platelet 
derived growth factor receptor alpha (PDGFR-α), forkhead box proteins-(FOXA2, FOXC2, 
FOXE1, FOXF1, FOXL1, FOXP3), POU class 3 homeobox1 (POU3F1), Runt-related 
transcription factor 2(RUNX2), SRY(Sex determoning region Y)- box13(SOX13) and T-
box2(TBX2) for cell fate determination and cancer proliferation and invasion-related 
genes(Katoh and Katoh, 2008). 
 
Hedgehog signaling pathway and its varied function in Tumorigenesis: 
 Hedgehog signaling pathway is an intermediary of the development transition participating in 
infinite aspects of cellular growth and proliferation. Thence, it is overt that deregulation of the 
pathway will lead to peculiar changes in the normal homeostatic changes. Abnormally, active 
HH signaling pathway edge to initiation, proliferation and progression of cancer either by a 
ligand-dpendent or a ligand-independent manner(Kar et al., 2012). So these two approaches are 
important in HH signaling pathway. 
 
Ligand dependent manner: There are two access in this condition, first one is during autocrine 
pathway HH ligand is over-expressed by tumor cells and performed on neighbouring cells to 
activate their multiplication. This type of mechanism is active in lung cancer, gastrointestinal 
cancer, pancreatic cancer, prostate cancer etc. the access is more arduous and implicates a paracrine 
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miniature where the epithilium secretes the HH ligand and stimulates the elemental stromal cubicle 
to undergo neoplastic differences. 
 
Ligand-independent manner: In this the genetic and epigenetic alteration plays a more decisive 
role. The HH pathway comprises of PTCH, SUFU, SMO and GLI undergo genetic alteration such 
as loss-of-function mutations in PTCH and SUFU, stimulating gain-of-function mutations in SMO 
and missense mutations in GLI1 and GLI3 has been largely cite in an ample variety of cancer. But 
epigenetic alteration of HH signaling pathway has recently come into climax. Promoter DNA hyper 
methylation of HH pathway components such as PTCH, SUFU, also transcriptional activation of 
SHH and GLI1 via loss of methylation are comes under epigenetic alteration. Higher expression of 
GLI1 in a subspace of medulloblastoma and glioblastoma cell lines has been reported (Shahi et al., 
2008). Promoter hyper methylation of SHH is a crucial root of gastric carcinogenesis (Wang et al., 
2006). Thus it is clearly noticeable that both genetic and epigenetic alterations are functional to 
rattle the HH pathway in cancer. This whole can be simplified in a diagrammatic way. The both 
ligand-dependent and ligand-independent manner can be described by the following systemic 
pathway. In the below figure we have discussed the autocrine, paracrine, mutated pathway and the 
inverse paracrine. Ligand-independent is different from that of ligand dependent manner because in 
case of ligand-independent manner there are loss-of-mutation and gain-of-mutation activity takes 
place. While in ligand-dependent manner there are two approaches like autocrine and paracrine so 
this has been shown in the figure with each different pathway. Autocrine signaling is a process of 
signaling in which a cell secretes a hormone or a product that binds to the autocrine receptor on that 
same cell. Autocrine signaling is a helping key for a death taking disease like cancer. As it has been 
mentioned many times that tumor development is a complex process that requires cell division, 
growth and survival. So tumors tendency is to have autocrine signaling so that they can proliferate 
at a rapid rate. Autocrine signaling plays critical roles in cancer activation and also in providing 
self-sustaining growth signals to tumors (adapted from wikipedia). 
                               
                             Paracrine signaling is a form of communication between cells in which a cell 
produces a signal to induce changes in surrounding cells, changing the behaviour or differentiation 
of those cells. Paracrine signaling both promotes and inhibits tumour proliferation and progression. 
Thus autocrine contrasts to paracrine in various ways. Paracrine and autocrine are descripted by the 
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figure given below. Their role in cell signaling and endrocine systems is totally different. The signal 
produced by paracrine can act on distant cells and thus it can be an advantage. Whereas the 
autocrine signaling acts on the same cell and thus the tumor progression can be benefitted by this. 
 
 
 
Figure 3: (a) Ligand-independent pathway stimulation occurs as a result of loss-of-function 
mutations in the negative regulators PTCH or SUFU or gain-of-activation occurs when HH 
ligand, produced by the tumor cell, activates HH signaling in the same cell. (c) Ligand-
dependent paracrine activation occurs when HH ligands secreted by tumor cells turn on HH 
signaling in the surrounding stroma then stimulates growth of the tumor. (d) Ligand-dependent 
inverse paracrine signaling occurs when stroma-derived HH ligand activates HH signaling in the 
tumor. (Adapted from wikipedia). 
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Paradigm of abnormal HH signaling pathway in Prostate cancer: 
The Hedgehog (HH) family of intercellular signaling proteins has come to be identified as 
primary mediators in many basic processes in embryonic development. The growth, patterning 
and morphogenesis of many different regions within the bodies of vertebrates are their central 
activities (Aparicio et al.,). Prostate cancer, the life threatening cancer related to death which is 
mostly common in men and found as solid tumors. In prostate cancer the abnormal HH signaling 
pathway mainly plays role. HH signaling with androgen signaling act concomitantly to stimulate 
prostate patterning deregulated HH signaling might be involved in prostate cancer. It is very 
familiar that prostatic tumor cells are originated from the anomalic spreading of normal prostatic 
epithelium; Henceforth in adult prostate epithelial cells the elevated activation of HH signaling 
acts in an autocrine fashion which promotes proliferation, progression and metastasis of prostate 
cancer cells. In endoderm derived cancers, there is a constitutive aberrant activation of the HH 
pathway, like the prostate is usually in response to endogenous over-expression of HH ligands 
such as SHH instead of inactivating somatic mutations in HH pathway components as PTCH, 
SMO or GLI. The deregulation of SHH-GLI pathway which mediates androgen-independent 
growth of prostate cancer by directly counteract with androgen receptor. The transition of 
prostate cancer from an androgen dependent to an androgen-independent state occur through the 
HH signaling either by compensating or even superseding androgen signaling. Recent studies 
have reported that paracrine HH signaling involve in progression of prostate tumors into 
therapeutically resistant state which is called as Castration recurrent prostate cancer (Kar et al., 
2012). CPRC tumor cells is encouraged by the component of HH signaling SHH for utilizing 
their endogenous androgen signaling system to derive their growth by interacting directly with 
the androgen receptors on stromal cells in the tumor microenvironment. Thus SHH play a key 
role in the development of Prostate cancer.  
 
          Activation of Hedgehog (HH) signaling is depicted in the development and proliferation of 
several tumor types, including prostate cancer, which are the most common non-skin malignancy 
and the third leading cause of cancer-related mortality in men around countries worldwide. It has 
been already mentioned that the HH pathway plays an important role in the development as well 
as in the proliferation of this disease to more powerful and even therapy-resistant disease states. 
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Also, preclinical data have shown that inhibition of HH signaling has the potential to reduce 
prostate cancer invasiveness and metastatic potential. According to (Haustermans et al., 2013) 
clinical trials investigating the benefit of HH inhibitors in patients with prostate cancer have 
recently been initiated. In other different types of tumor drug resistance has already been 
observed after HH inhibition. Therefore, when ionizing radiation, chemotherapy or other 
molecular targeted agents combined with HH inhibitors could represent an alternative 
therapeutic strategy. HH signaling plays an important role in the embryonic development of the 
prostate. HH signaling is actively present in the epithelium of the urogenital sinus from where 
the prostate derives. According to (Burman et al., 2004) during prostate development, HH 
signaling mainly functions in the ductal budding and ductal extension, but is also important for 
tissue polarity. HH signaling is relatively low in the adult prostate but still present and important 
for regeneration of prostate epithelium. Various evidence suggests an active role for HH 
signaling in the development and proliferation of Prostate cancer. Within chromosomal regions 
multiple components of the HH pathway are present which are associated with susceptibility to 
human Prostate cancer. According to (sheng et al., 2004), loss-of function mutations in SUFU 
are the only known mutations in the HH pathway in prostatic tumor tissues thus far. Generally, in 
prostate tumors aberrant HH signaling is believed to be ligand-dependent. On the other hand 
(Shaw et al., 2000), there are data suggesting that the tumor switches to an autocrine requirement 
for HH signaling in which the tumor cells both produce and respond to the ligand. It could also 
be that in some cases paracrine and autocrine mechanisms co-exist, so that overexpression of HH 
by the tumor cells orchestrates effective tumor growth by direct stimulation of tumor cell 
proliferation.  According to (Sheng et al., 2004) it has been reported that high levels of Ptch1 and 
Hedgehog-interacting protein (HHip) were more frequently detected in Prostate cancer with high 
Gleason score and metastatic Prostate cancer specimens.  Moreover (Tzepeli et al., 2011) 
demonstrated that expression of Ptch in the tumor tissue correlated with tumor grade and stage. 
           
 
 
 
12 
 
 
OBJECTIVES OF THE PROJECT 
1. Study of the gene expression status of the different Hedgehog signaling pathway 
components - SHH, SMO, PTCH, GLI1 in PC3 and Du145 Prostate cancer cell lines. 
 
2. Study of the effect of various epigenetic modulators such as AZA (inhibitor of DNMT), 
TSA (Histone deacetylase inhibitors) and Cyclopamine (CPA) (HH antagonists) on the 
survival and growth characteristics of DU145 Prostate cancer cell line. 
 
3. Comparative analysis of the effect of various epigenetic modulators and Cyclopamine on 
the expression of the different Hedgehog pathway components after treatment. 
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MATERIALS AND METHODS 
 
1. In vitro cell culture: 
 
Human Prostate cancer cell lines PC3 and DU145 were cultured and maintained in F12 and 
Dulbecco’s Modified Eagle’s Medium (DMEM, Invitrogen) respectively supplemented with 
10% (v/v) Fetal Bovine Serum (FBS, Invitrogen) and 100 IU/mL penicillin and 0.1 mg/mL 
streptomycin in a humified atmosphere of 5% CO2 at 37°C. 
 
 
2. Treatment with epigenetic drugs –AZA, TSA, and Cyclopamine: 
  
Stock solutions of AZA, TSA and Cyclopamine were prepared in dimethylsulphoxide (DMSO, 
Sigma). Cells were harvested by trypsinization and cell number was counted by 
haemocytometer. For determining the concentration of drug that inhibited cell proliferation by 
50% (IC50), 5 X 10
3
 cells per well were seeded in 96-well microtiter plate and after 24 h 
incubation, were treated with the epigenetic modulators at different concentrations (Table1) 
mixed in DMEM supplemented with 5% FBS. Control cells were treated with DMSO only. The 
cells were then incubated for 24 and 48 h. 
 
Table 1: Different concentrations of the various epigenetic drugs considered for MTT assay 
                      DRUGS              CONCENTRATION 
                        AZA 5, 7.5, 10, 12.5, 15, 17.5, 20, 25 μM 
                        TSA 50, 100, 150, 200, 300, 350, 400 Nm 
                   Cyclopamine 5, 7.5, 10, 12.5, 15, 17.5, 20, 25 μM 
 
 
3. Cell Viability Analysis by colometric MTT Assay: 
 
The effect of the epigenetic drugs on cellular proliferation was assessed by 3-(4, 5-
Dimethylthiazol-2-yl)-2, 5-Diphenyltetrazolium Bromide (MTT, Sigma) assay, using standard 
protocol. The MTT assay is based on the observation that the mitochondria in living cells can 
catalyze MTT molecules to a colorimetrically detectable dye. Briefly, the drug treated cells in 
each of the 96 wells were washed twice with PBS. 0.8 mg/mL MTT solution was prepared from 
14 
 
stock MTT solution (5 mg/mL PBS, pH 7.2). 100 μL MTT solutions was added to each well and 
incubated at 37º C for 4 h in dark. The supernatant was removed and 100 μL of DMSO was 
added into each well to dissolve the formazan crystals. The absorbance was measured at 570 nm 
and results were expressed as the mean of three replicates as a percentage of control (taken as 
100%).The extent of cytotoxicity was defined as the relative reduction of the optical density 
(OD), which correlated to the amount of viable cells in relation to cell control (100%). The 
absorbance was plotted in a graph and the IC40 was calculated accordingly to decide the optimum 
dosage of the drugs for further studies. 
 
4. Chromatin condensation analysis by Hoechst staining: 
 
After treatment with epigenetic modulators at the IC50 concentration, cells were stained with 
Hoechst 33342 stain (1 mg/ml, Invitrogen) followed by incubation for 10 mins at 37
0
C. Images 
were taken under UV filter using Epi-fluorescent Microscope (Olympus IX71) at 400 X 
magnification with an excitation wavelength of 355-366 nm and an emission wavelength of 465-
480 nm. Condensed nuclei were counted against total number of nuclei in the field, and the 
percentage of apoptotic nuclei were calculated and plotted graphically. 
 
5. Scratch and Migration Assay: 
 
The effect of various epigenetic modulators on the wound healing and cell migration was 
assessed by scratch and migration assay. Approximately 10
6
 cells were seeded onto 6-well plates 
and incubated for 24 h. A scratch was done with the help of a sterile tip, media was removed and 
then the cells were washed twice with PBS and then treated with the IC40 values of the various 
epigenetic drugs. The cells were then incubated for 24 h and then images were taken using Epi-
fluorescent Microscope (Olympus IX71) at 10X magnification. 
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6. Extraction of Total RNA: 
 
DU145 cell lines were treated with sub lethal dosages of the various epigenetic drugs for 24 h. 
After treatment for the required time, total RNA was extracted using the Trizol (Sigma) reagent 
according to the manufacturer’s instructions. The drug treated cells (5-10 X 106 cells) were 
washed with 1 ml ice cold PBS, then trypsinized and then treated with 1 ml Trizol. 0.2 ml of 
chloroform (Sigma) (0.2 ml per 1 ml of TRI Reagent) was added to the tubes, shaken vigorously 
for 30 seconds by hand/vortex mixer and incubated at RT for 10 minutes. The samples were 
centrifuged at 12,000 x g for 15 minutes at 4°C. Following centrifugation, the mixture separates 
into lower red, phenol-chloroform phase, an interphase, and a colorless upper aqueous phase 
containing the RNA. The upper aqueous phase was removed without disturbing the interphase 
and collected in a fresh tube. 0.5 ml isopropyl alcohol (Sigma) per 1 ml of TRI Reagent was 
added to the tubes. The tubes were then incubated at RT for 10 minutes and then centrifuged at 
not more than 12,000 x g for 10minutes at 4° C. The supernatant was removed completely. The 
RNA precipitate, often invisible before centrifugation, forms a gel-like pellet on the side and 
bottom of the tube. The pellet was washed with 1ml of 75% ethanol per 1 ml of TRI Reagent. 
The samples were mixed by vortexing and centrifuged at no more than 7,500 x g for 5 minutes 
4° C. The pellet was air-dried by keeping the RNA pellet containing tube opened in working 
bench for 15 minutes. The RNA was dissolved in 50 μl DEPC-treated water by passing solution 
a few times through a pipette tip. The RNA was stored at -20° C for further use or immediately 
processed for cDNA synthesis. 
 
7. Quantitative Estimation of RNA Concentration by Spectrophotometric Analysis: 
 
The concentration of the extracted total RNA was quantified by measuring the absorbance at 260 
nm in a spectrophotometer (ELICO, BL 200 Bio Spectrophotometer, double beam) and 
calculated by using the formula as given below: 
              Total RNA (μg /ml) = OD260 × 40 × Dilution factor. 
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8. First strand cDNA synthesis: 
 
Total RNA (2 μg) was used for first strand cDNA synthesis by reverse transcription  using  
RevertAidTM First  Strand cDNA Synthesis Kit (Fermentas) in a thermocycler (Biorad). The 
RNA was incubated with 1 μl of oligo (dT) 18 primers (100 μM, 0.2μg/μl) and 12 μl of nuclease-
free water at 65º C for 5 minutes. The reaction was cooled on ice to allow the primers to anneal 
to the RNA, then spun down and placed on ice again after which the following components were 
added to the reaction in order; 4 μl of 5X Reaction Buffer, 1 μl of RibolockTM RNase inhibitor 
(20 U/μl), 2 μl of 10 mM dNTPs and 1.0 μL of RevertAidTM M-MuLV-Reverse Transcriptase 
(200 U/μl). The reagents were gently mixed and incubated for 1 h at 42º C. Heating at 70º C for 
5 minutes terminated the reaction and the synthesized cDNA was stored at –20º C for further use. 
 
9. Gene-specific semi-quantitative PCR for amplification of the desired genes: 
 
The PCR reaction mixtures, in a 25 μl volume, contained 17 μl of dH2O (Sigma), 2.5 μl of 1X 
PCR buffer (Sigma), 0.5 μl of dNTP (0.2 mM, Sigma), 1.5 μl of MgCl2 (1.5 mM, Sigma), 0.5 μl 
each of the forward and reverse primers (0.2 μM, Sigma) of SHH, PTCH, SMO, GLI1, 0.5 μl 
Taq DNA-polymerase (1U/μl, Himedia). 2 μl of each cDNA sample was added. PCR 
amplifications were performed in a thermal cycler (Biorad) by initial denaturation at 94° C for 1 
min, followed by 30 cycles of denaturation at 94° C for 20 secs, annealing at 58° C for 20 secs, 
and extension at 72° C for 30 secs, followed by an final extension step at 72° C for 5 minutes. 
The constitutively expressed housekeeping gene, β-actin was used as a positive control to ensure 
high quality. RT-PCR products were then analyzed by 1% agarose gel electrophoresis containing 
ethidium bromide (0.05%). The primer sequences for the PCR reaction are shown in Table 2. 
 
10. Relative Gene Expression Analysis after drug treatment by Real-Time PCR: 
 
Quantitative estimation of the expression of the DU genes after drug treatment was done via real-
time PCR analysis. qRT-PCR was performed using cDNA prepared from 1μg of total RNA 
prepared using RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific) and SYBR® 
Green JumpStart™ Taq ReadyMix (Sigma) in the Realplex4Eppendorf system. The mRNA level 
was normalized to β-actin. The primer sequences are provided in Table 2. 
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Table2: List of sequence and product length of the Real-Time PCR Primers 
 
List of sequence and product length of the Real-Time PCR Primers 
Gene Primer sequence Tm Product 
SHH 
F 5’-- CCAAAGCGTTCAACTTGTCC--3’ 57.88 
112 bp 
R 5’—TTTAAGGAACTCACCCCCAA--3’ 56.24 
PTCH 
F 5’—TCTCCAATCTTCTGGCGAGT—3’ 58.44 
106 bp 
R 5’—TGGGATTAAAAGCAGCGAAC--3’ 56.71 
SMO 
F 5’ – CAACCTCTTTGCGTTTCCTT—3’ 56.84 
154 bp 
R 5’—ACTCACTGCTCCTATCCCACTC—3’ 60.95 
GLI1 
F 5’ – AGGGAGTGCAGCCAATACAG--3’ 59.75 
171 bp 
R 5’—ATTGGCCGGAGTTGATGTAG--3’ 57.67 
β-
ACTIN 
F 5’- CTGGAACGGTGAAGGTGACA -3’ 58.12 
140 bp 
R 5’- AAGGGACTTCCTGTAACAACGCA -3’ 58.35 
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RESULTS AND DISCUSSION 
 
1.   Cell Viability Analyses by colometric MTT Assay 
Epigenetic modulators inhibit cell growth in PC3 and Du145 prostate cancer cell lines in a 
dose and time dependent manner. 
The effect of the various epigenetic modulators -- AZA, TSA, and CPA on the cell 
viability after 24 and 48 h treatment was assessed by colorimetric MTT assay. The epigenetic 
modulators (TSA, AZA and CPA) have their own distinct effect on cell viability at different 
concentrations. The results obtained from MTT assay are given below (Fig.4).                                            
 
                                                                           48h 
 
 
Figure 4: The effect of different concentration of DNMT modulator, HDAC inhibitor and HH 
antagonist after 24h and 48h. 
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Table 3: IC50 concentrations of epigenetic modulators used against PC3 and Du145. 
 
2. Chromatin condensation analysis after drug treatment by Hoechst staining 
Epigenetic modulators promote apoptotic cell death in PC3 and Du145 cells. 
Nuclear chromatin condensation analysis of drug treated PC3 and Du145 cells by 
Hoechst staining was performed to analyzing the cytotoxic effect of the epigenetic modulators 
on the cell survival. Both the cell lines PC3 and Du145 were treated with IC50 concentration 
of the epigenetic drugs for 24 and 48 h to study their effect on cell cycle and cell growth. It 
is observed that all the epigenetic modulators promote apoptotic cell death in cells as is 
evident form increased chromatin condensation which is a distinct characteristic of apoptotic 
cells. The results of Hoechst staining assay are given below (Fig. 5 (a, b)). 
 
 
Figure5: (a) Nuclear chromatin condensation in treated PC3 cells after 24 h.          
Panel [I] representative images of Hoechst 33342 stained nuclei, 
Panel [II] percentage of condensed nuclei represented graphically. 
DRUG IC50  IN PC3 IC50 IN Du145 
AZA 15µM 15µM 
TSA 150nM 150Nm 
CPA 25µM 25µM 
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Figure 5(b): Nuclear chromatin condensation in treated Du145 cells after 24h 
The chromatin becomes inert, highly condensed, undergoes fragmentation and gets packaged 
into apoptotic bodies during apoptosis. Blue-fluorescent Hoechst 33342 dye which 
brightly stains the highly condensed and the morphological changes induced by 
apoptosis can be observed. After treatment with the epigenetic modulators at specific 
concentrations—AZA (15 μM), TSA (150 nM) and CPA (25 μM), percentage of condensed 
nuclei are 28.36% (AZA), 48.45% (TSA), and 42.67% (CPA), whereas in control cells exhibit 
6.94% condensed nuclei (Fig. 5 (a), panel II). In case of Du145 cells, the percentage of 
condensed nuclei was 35.67% (AZA), 53.42% (TSA), 44.54% (CPA), whereas in 
control cells exhibit 12.34% condensed nuclei (Fig. 5(b), panel II). The percentage of 
condensed nuclei is highest in TSA and CPA treated cells for both the cell lines, hence, and it 
has been observed that TSA and CPA are seen to be highly effective in inducing apoptosis in 
prostate cancer cells. 
 
 
 
 
 
 
21 
 
3.   Flow Cytometry Analysis of the effects of epigenetic drugs on cell cycle 
(FACS) 
 
Epigenetic modulators induce G2-M arrest and apoptosis in PC3and Du145 cells. 
           The cell cycle and cell growth is important, so to observe flow cytometry based cell 
cycle analysis of PC3 and Du145 after treatment for 24h and 48h with epigenetic modulators 
was performed. There is an alteration in the cell cycle distributions in both the cell lines (Fig. 
6(a, b)). In case of PC3, percentage of G1, S, G2/M and apoptotic cells is 25.3%, 8.3%, 13.6% 
and 4.5% respectively for untreated control cells in case of 24h and for 48h, 26.3%, 7.8%, 
11.3% and 5.4% respectively. After treatment with AZA (15 μM), the percentage of G1, S, 
G2/M and apoptotic cells is found to be 28.9%, 7.1%, 15.6% and 8.1%(in case of 24h 
treatment) and 29.3%, 6.5%, 17.6% and 10% (in case of 48h) respectively . After treatment 
with TSA(150 nM), the percentage of G1, S, G2/M and apoptotic cells is found to be 12.3%, 
4.5%, 11.2% and 6.7% (in case of 24h treatment) and  13.2%, 8.6%, 14.5% and 8.3% (in case 
of 48h treatment) respectively. After treatment with CPA(25 μM), the percentage of G1, S, 
G2/M and apoptotic cells is found to be 23.4%, 6.7%, 10.9% and 4.8% (in case of 24h 
treatment) and 21.4%, 4.3%, 7.9% and 5.9%(in case of 48h treatment) 
respectively
 
Figure 6(a): Cell cycle distribution of PC3 after treatment with different epigenetic                            
modulators for 24 h and 48 h 
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Du145 cells were also treated with various epigenetic modulators and the cell population was 
assessed after 24 h and 48h. In case of controls cells, the percentage of G1, S, G2/M and 
apoptotic cell population were found to be 15.9%, 5.6%, 7.8% and 3.6%(in case of 24h 
treatment) and 11.4%, 4.6%, 6.1% and 5.3%(in case of 48h treatment) respectively. After 
treatment with AZA(15 μM), the percentage of G1, S, G2/M and apoptotic cell population were 
seen to be 13.2%, 2.5%, 5.2% and 9.1% (in case of 24h treatment) and 11.5%, 2.4%, 4.6% and 
15.3% (in case of 48h treatment) respectively. In case of TSA treatment, 9.1%, 1.9%, 4.6% and 
15.3% (in case of 24h treatment) and 14.5%, 2.5%, 5.4% and 22.4% (in case of 48h treatment) 
respectively. After CPA (25 μM) treatment, the percentage of G1, S, G2/M and apoptotic cell 
population were found to be 11.2%, 2.9%, 4.8% and 18.9% (in case of 24h treatment) and 
8.5%, 3.1%, 4.6% and 21.6% (in case of 48h treatment) respectively. 
 
Figure 6(b): Cell cycle distribution of Du145 cell population after treatment for 24 h. 
 
In comparison to control untreated cells, cells treated with AZA show decrease in G1-phase 
cells, decreased percentage of S and G2 population. Additionally, cells treated with TSA and 
CPA exhibit reduction in G1 phase cells, decrease in percentage of G2 population and drastic 
increase in apoptotic cell population. 
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4.  Scratch and Migration Assay after drug treatment 
 
Epigenetic modulators affect wound healing ability of PC3 and Du145 cells. 
 
Scratch and migration is done for wound healing potential of prostate cancer cell line (PC3 and 
Du145) observation which was treated with epigenetic modulators for 24h and 48h. Both the cell 
lines were treated with IC50 concentration of the epigenetic drugs for 24 and 48 h to study 
their effect on cancer cell motility. It is observed that different epigenetic drugs have differential 
effects on the migration ability of both cell lines. Du145 cells, being moderate metastatic stage 
cell line showed less migration in comparison to PC3 cell which are highly metastatic and have 
high migratory ability. The results of scratch assay are given below (Fig. 7). 
 
 
 
 
 
 
 
 
 
Figure7: (a) PC3 Cell line (b) Du145 cell line
           (a) PC3 Cell line                                                                             (b) Du145 cell line 
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5.   Relative Gene Expression Analysis after drug treatment by RT-PCR 
 
The effect of the epigenetic modulators on the expression of HH pathway genes in both 
PC3 and Du145 cells was determined by the quantitative analysis of mRNA after treatment. In 
case of PC3, the transcript level of SHH shows increase of 9.3 fold (in case of 24h) and 7.4(in 
case of 48h) after treated with AZA (15 μM), after TSA (150 nM), of 6.9 (in case of 24h) and 
7.1(in case of 48h) and after CPA (25 µM), of 8.7 fold (in case of 24h) and 6.4 fold (in case of 
48h). The transcript level of SMO shows increase of 5.6 fold (in case of 24h) and 7.1(in case of 
48h) after treated with AZA (15 μM), after TSA (150 nM), of 8.1 (in case of 24h) and 5.6 fold (in 
case of 48h) and after CPA (25 µM), of 3.6 fold (in case of 24h) and 2.9 fold (in case of 48h). 
The transcript level of PTCH shows increase of 13.5 fold (in case of 24h) and 16.5 fold (in case 
of 48h) after treated with AZA (15 μM), after TSA (150 nM), of 5.8 fold (in case of 24h) and 4.9 
fold (in case of 48h) and after CPA (25 µM), of 9.1 fold (in case of 24h) and 8.6 fold (in case of 
48h). The transcript level of GLI shows increase of 2.3 fold (in case of 24h) and 4.6 fold (in case 
of 48h) after treated with AZA (15 μM), after TSA (150 nM), of 2.3 fold (in case of 24h) and 1.9 
fold (in case of 48h)and after CPA (25 µM) of 3.9 fold (in case of 24h) and 1.2 fold (in case of 
48h).  
  
 
 
 
 
 
                     Figure 8(a): Relative fold change in PTCH, SHH, SMO and GLI w.r.t β-actin  
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                              In case of Du145, the transcript level of SHH shows increase of 8.3 fold (in case 
of 24h) and 9.8 fold (in case of 48h) after treated with AZA (15 μM), after TSA (150 nM), of 8.3 
fold (in case of 24h) and 5.6 fold (in case of 48h) and after CPA (25 µM), of 8.3 fold (in case of 
24h) and 7.4 fold (in case of 48h). The transcript level of SMO shows increase of 7.6 fold (in case 
of 24h) and 8.1 fold (in case of 48h) after treated with AZA (15 μM), after TSA (150 nM), of 6.3 
fold (in case of 24h) and 5.6 fold (in case of 48h) and after CPA (25 µM), of 4.2 fold (in case of 
24h) and 2.9 fold (in case of 48h). The transcript level of PTCH shows increase of 11 fold (in case 
of 24h) and 10.3 fold (in case of 48h) after treated with AZA (15 μM), after TSA (150 nM), of 9.8 
fold (in case of 24h) and 9.3 fold (in case of 48h) and after CPA (25 µM), of 5.6 fold (in case of 
24h) and 3.9 fold (in case of 48h). The transcript level of GLI shows increase of 8.6 fold (in case 
of 24h) and 9.1 fold (in case of 48h) after treated with AZA (15 μM), after TSA (150 nM), of 3.4 
fold (in case of 24h) and 2.9 fold (in case of 48h) and after CPA (25 µM) of 7.9 fold (in case of 
24h) and 9.3 fold (in case of 48h).  
          Figure 8(b): Relative fold change in PTCH, SHH, SMO and GLI w.r.t β-actin  
After treatment with epigenetic drugs, the level of transcript expression of HH pathway components 
has consistently increased for every drug treatment. 
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CONCLUSION 
This study was designed to investigate the effects of epigenetic modulators and Hedgehog 
inhibitors on the gene expression and function of hedgehog pathway components and also 
elucidate their effect on prostate cancer cell lines. All the three administered drugs exhibit dose 
and time-dependent cell survival properties. With increasing time and the dosage, cell viability 
gradually decreases. It is seen that TSA and CPA have almost identical effect on the cells albeit at 
different concentrations where cell viability is drastically reduced at high concentrations. After 
treatment with the above-mentioned drugs, it is seen that the chromatin undergoes rapid 
degradation and percentage of condensed nuclei rises in comparison to untreated cells. Scratch 
and Migration assay showed that CPA treated cells exhibited the least wound healing ability; 
hence can be considered to be highly effective drugs against prostate cancer cells. In FACS 
analysis, it was observed that TSA and CPA treated cells showed the highest rates of apoptosis. 
The relative gene expression analysis showed that the level of expression of the four HH 
component genes varied according to the type of drug treatment and time of treatment. Thus, it is 
seen that epigenetic drugs as well as Cyclopamine affect the gene expression of HH signaling 
pathway components as well as affect cell growth and viability of prostate cancer cells. Further 
studies on protein expression in drug treated cells will help to substantiate these observations. The 
deciphering of the epigenetic machinery behind HH pathway deregulation in cancer will be a 
novel approach to inhibit or restrict this pathway in cancer. 
  
27 
 
REFERENCES 
 
1. Beachy, P. A., Hymowitz, S. G., Lazarus, R. A., Leahy, D. J. and Siebold, C. (2010). 
Interactions between Hedgehog proteins and their binding partners come into view. Genes 
Dev. 24(18); 2001–2012. 
 
2. Bian, Y. H., Huang, S. H., Yang, L., Ma, X. L., Xie, J.W. and Zhang, H.W. (2007). Sonic 
hedgehog-Gli1 pathway in colorectal adenocarcinomas. World J Gastroenterol. 13 (11), 
1659-1665. 
 
3. Hatsell, S. and Frost, A. R. (2007). Hedgehog Signaling in Mammary Gland Development 
and Breast Cancer. J Mammary Gland Biol Neoplasia. 12, 163–173. 
 
4. Jacob, J. and Briscoe, J. (2003).GLI proteins and the control of spinal-cord patterning. 
EMBO Rep. 4(8); 761–765. 
 
5. Jiang, J. and Hui, C. (2008). Hedgehog Signaling in Development and Cancer. 
Developmental Cell. 15, 801-812. 
 
6. Kar S, Deb M, Sengupta D, Shilpi A, Bhutia SK, Patra SK. (2012). Intricacies of 
Hedgehog signaling pathways: A perspective in tumorigenesis. Exp Cell Res., 318: 1959-
1972. 
 
7.Fan, L.; Pepicelli, C.V.; Dibble, C.C.; Catbagan, W.; Zarycki, J.L.; Laciak, R.; Laciak, R.; 
Gipp, J.; Shaw, A.; Lamm, M.L.G.; et al. Hedgehog signaling promotes prostate xenograft 
tumor growth. Endocrinology 2004, 145, 3961–3970. 
 
8. Lamm, M.L.; Catbagan, W.S.; Laciak, R.J.; Barnett, D.H.; Hebner, C.M.; Gaffield, W.; 
Walterhouse, D.; Iannaccone, P.; Bushman, W. Sonic hedgehog activates mesenchymal Gli1 
expression during prostate ductal bud formation. Dev. Biol. 2002, 249, 349–366. 
 
28 
 
9. Freestone, S.H.; Marker, P.; Grace, O.C.; Tomlinson, D.C.; Cunha, G.R.; Harnden, P.; 
Thomson, A.A. Sonic hedgehog regulates prostatic growth and epithelial differentiation. Dev. 
Biol. 2003, 264, 352–362. 
 
10. Berman, D.M.; Desai, N.; Wang, X.; Karhadkar, S.S.; Reynon, M.; Abate-Shen, C.; 
Beachy, P.A.; Shen, M.M. Roles for Hedgehog signaling in androgen production and prostate 
ductal morphogenesis. Dev. Biol. 2004, 267, 387–398. 
 
11. Sheng, T.; Li, C.; Zhang, X.; Chi, S.; He, N.; Chen, K.; McCormick, F.; Gatalica, Z.; Xie, 
J. Activation of the hedgehog pathway in advanced prostate cancer. Mol. Cancer 2004, 3, 29. 
 
12.Tzelepi, V.; Karlou, M.; Wen, S.; Hoang, A.; Logothetis, C.; Troncoso, P.; Efstathiou, E. 
Expression of hedgehog pathway components in prostate carcinoma microenvironment: 
shifting the balance towards autocrine signalling. Histopathology 2011, 58, 1037–1047. 
 
13. Mimeault, M., Moore, E., Moniaux, N., Hénichart, J. P., Depreux, P., Lin, M. F., & Batra, 
S. K. (2006). Cytotoxic effects induced by a combination of cyclopamine and gefitinib, the 
selective hedgehog and epidermal growth factor receptor signaling inhibitors, in prostate 
cancer cells. International journal of cancer, 118(4), 1022-1031. 
 
14. Mimeault, M., Johansson, S. L., Henichart, J. P., Depreux, P., & Batra, S. K. (2010). 
Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and 
nonside population cell fractions from human invasive prostate cancer cells. Molecular 
cancer therapeutics, 9(3), 617-630. 
 
15. Shah, R. B., Ghosh, D., & Elder, J. T. (2006). Epidermal growth factor receptor (ErbB1) 
expression in prostate cancer progression: correlation with androgen independence. The 
Prostate, 66(13), 1437-1444. 
 
16. Di Lorenzo, G., Tortora, G., D’Armiento, F. P., De Rosa, G., Staibano, S., Autorino, R., 
& Ciardiello, F. (2002). Expression of epidermal growth factor receptor correlates with 
29 
 
disease relapse and progression to androgen-independence in human prostate cancer. Clinical 
Cancer Research, 8(11), 3438-3444. 
 
17.Van Leenders, G. J., Gage, W. R., Hicks, J. L., van Balken, B., Aalders, T. W., Schalken, 
J. A., & De Marzo, A. M. (2003). Intermediate cells in human prostate epithelium are 
enriched in proliferative inflammatory atrophy. The American journal of pathology, 162(5), 
1529-1537. 
 
18. Chen, B. Y., Lin, D. P. C., Liu, J. Y., Chang, H., Huang, P. H., Chen, Y. L., & Chang, H. 
H. (2006). A mouse prostate cancer model induced by Hedgehog overexpression. Journal of 
biomedical science, 13(3), 373-384. 
19. Sheng, T., Li, C., Zhang, X., Chi, S., He, N., Chen, K., ... & Xie, J. (2004). Activation of 
the hedgehog pathway in advanced prostate cancer. Molecular cancer, 3(1), 29. 
20. Sanchez, P., Hernández, A. M., Stecca, B., Kahler, A. J., DeGueme, A. M., Barrett, A., ... 
& i Altaba, A. R. (2004). Inhibition of prostate cancer proliferation by interference with 
SONIC HEDGEHOG-GLI1 signaling. Proceedings of the National Academy of Sciences of 
the United States of America, 101(34), 12561-12566. 
21. Sanchez, P., Clement, V., & i Altaba, A. R. (2005). Therapeutic targeting of the 
Hedgehog-GLI pathway in prostate cancer. Cancer research, 65(8), 2990-2992. 
22. Mimeault, M., Mehta, P. P., Hauke, R., Henichart, J. P., Depreux, P., Lin, M. F., & Batra, 
S. K. (2007). Improvement of cytotoxic effects induced by mitoxantrone on hormone-
refractory metastatic prostate cancer cells by co-targeting epidermal growth factor receptor 
and hedgehog signaling cascades. Growth Factors, 25(6), 400-416. 
23. Mimeault, M., Johansson, S. L., Vankatraman, G., Moore, E., Henichart, J. P., Depreux, 
P., & Batra, S. K. (2007). Combined targeting of epidermal growth factor receptor and 
hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic 
effects of docetaxel on metastatic prostate cancer cells. Molecular cancer therapeutics, 6(3), 
967-978. 
24. Paul, R., & Breul, J. (2000). Antiandrogen withdrawal syndrome associated with prostate 
cancer therapies. Drug safety, 23(5), 381-390. 
30 
 
25. Rambeaud, J. J. (1998). Intermittent complete androgen blockade in metastatic prostate 
cancer. European urology, 35, 32-36. 
 
26. Sciarra, A., Casale, P., Colella, D., Di Chiro, C., and Di Silverio, F. (1999) Hormone 
refractory prostate cancer? Anti-androgen withdrawal and intermittent hormone therapy. 
Scand. J. Urol. Nephrol. 33, 211–216. 
 
27. Russell, P. J., & Kingsley, E. A. (2003). Human prostate cancer cell lines. In Prostate 
Cancer Methods and Protocols (pp. 21-39). Springer New York. 
 
28. Lara, P. N., Jr and Meyers, F. J. (1999) Treatment options in androgen-independent 
prostate cancer. Cancer Invest. 17, 137–144. 
 
 
29. Peterziel, H., Culig, Z., Stober, J., Hobisch, A., Radmayr, C., Bartsch, G.,  & Cato, A. C. 
(1995). Mutant androgen receptors in prostatic tumors distinguish between 
amino‐acid‐sequence requirements for transactivation and ligand binding. International 
journal of cancer, 63(4), 544-550. 
 
30. Wang, C. and Uchida, T. (1997) Androgen receptor gene mutations in prostate cancer. 
Jpn. J. Urol. 88, 550–556. 
 
31. Henshall, S. M., Quinn, D. I., Lee, C. S., Head, D. R., Golovsky, D., Brenner, P. C., ... & 
Sutherland, R. L. (2001). Altered expression of androgen receptor in the malignant 
epithelium and adjacent stroma is associated with early relapse in prostate cancer. Cancer 
Research, 61(2), 423-427. 
 
31 
 
32. Kinoshita, H., Shi, Y., Sandefur, C., Meisner, L. F., Chang, C., Choon, A., & Jarrard, D. 
F. (2000). Methylation of the androgen receptor minimal promoter silences transcription in 
human prostate cancer. Cancer research, 60(13), 3623-3630. 
 
33. Peehl, D. M. (1995). Prostate specific antigen role and function. Cancer, 75(S7), 2021-
2026. 
 
34. Cramer, S. D., Chen, Z., & Peehl, D. M. (1996). Prostate specific antigen cleaves 
parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP-
stimulated cAMP accumulation in mouse osteoblasts. The Journal of urology, 156(2), 526-
531. 
 
35. Xue, W., Irvine, R. A., Mimi, C. Y., Ross, R. K., Coetzee, G. A., & Ingles, S. A. (2000). 
Susceptibility to prostate cancer: interaction between genotypes at the androgen receptor and 
prostate-specific antigen loci. Cancer research, 60(4), 839-841. 
 
36. McCormack, R. T., Wang, T. J., Rittenhouse, H. G., Wolfert, R. L., Finlay, J. A., Lilja, 
H., ... & Oesterling, J. E. (1995). Molecular forms of prostate-specific antigen and the human 
kallikrein gene family: a new era. Urology, 45(5), 729-744. 
 
37. Chang, S. S., Reuter, V. E., Heston, W. D. W., Hutchinson, B., Grauer, L. S., & Gaudin, 
P. B. (2000). Short term neoadjuvant androgen deprivation therapy does not affect prostate 
specific membrane antigen expression in prostate tissues. Cancer, 88(2), 407-415. 
 
38. Russell, P. J., Bennett, S., & Stricker, P. (1998). Growth factor involvement in 
progression of prostate cancer. Clinical chemistry, 44(4), 705-723. 
 
32 
 
39. Kaighn, M. E., Narayan, K. S., Ohnuki, Y., Lechner, J. F., & Jones, L. W. (1979). 
Establishment and characterization of a human prostatic carcinoma cell line (PC-3). 
Investigative urology, 17(1), 16-23. 
 
40. Gleave, M. E., Hsieh, J. T., Wu, H. C., Hong, S. J., Zhau, H. E., Guthrie, P. D., & Chung, 
L. W. (1993). Epidermal growth factor receptor-mediated autocrine and paracrine stimulation 
of human transitional cell carcinoma. Cancer research, 53(21), 5300-5307. 
 
 
 
 
 
 
 
